Underutilization of gastroprotective measures in patients receiving nonsteroidal antiinflammatory drugs
Open Access
- 9 August 2002
- journal article
- research article
- Published by Wiley in Arthritis & Rheumatism
- Vol. 46 (8) , 2195-2200
- https://doi.org/10.1002/art.10425
Abstract
Objective To determine the frequency of use of recommended gastroprotective strategies in a cohort of patients receiving recurrent treatment with nonsteroidal antiinflammatory drugs (NSAIDs). Methods A cross-sectional study was performed using administrative data from the Tennessee Medicaid (TennCare) program. The study population consisted of 76,765 recurrent recipients of NSAIDs (NSAID users), comprising 24% of the 319,402 persons ages 50 years or older enrolled in the TennCare program from January 1999 through June 2000. Frequency of use of either of 2 recommended gastroprotective strategies, involving either traditional NSAIDs combined with recommended anti-ulcer cotherapy or use of a selective cyclooxygenase 2–inhibiting drug (coxib), was measured and categorized by risk for ulcer complication. Results Among this cohort of recurrent NSAID users, 16% received 1 of the 2 recommended gastroprotective therapies: 10% received traditional NSAIDs along with antiulcer drugs at the recommended doses and 6% received coxibs. Among those patients with ≥2 risk factors for ulcer complications (age 75 years or older, peptic ulcer or gastrointestinal bleeding in the past year, or concurrent use of oral anticoagulants or corticosteroids), 30% received such gastroprotective therapy. Conclusion Use of recommended strategies to decrease ulcer complications in vulnerable populations is relatively uncommon.Keywords
This publication has 22 references indexed in Scilit:
- Economic evaluation of rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs for the treatment of osteoarthritisClinical Therapeutics, 2001
- The economic implications of cyclooxygenase-2–specific inhibitorsThe American Journal of Medicine, 2001
- Economic Evaluation of Celecoxib, a New Cyclo-Oxygenase 2 Specific Inhibitor, in SwitzerlandPharmacoEconomics, 2001
- Incremental Cost-Effectiveness Analysis Comparing Rofecoxib with Nonselective NSAIDs in OsteoarthritisPharmacoEconomics, 2001
- Comparison of Upper Gastrointestinal Toxicity of Rofecoxib and Naproxen in Patients with Rheumatoid ArthritisNew England Journal of Medicine, 2000
- Gastrointestinal Toxicity With Celecoxib vs Nonsteroidal Anti-inflammatory Drugs for Osteoarthritis and Rheumatoid ArthritisJAMA, 2000
- A Comparison of Omeprazole with Ranitidine for Ulcers Associated with Nonsteroidal Antiinflammatory DrugsNew England Journal of Medicine, 1998
- Famotidine for the Prevention of Gastric and Duodenal Ulcers Caused by Nonsteroidal Antiinflammatory DrugsNew England Journal of Medicine, 1996
- Effects of Limiting Medicaid Drug-Reimbursement Benefits on the Use of Psychotropic Agents and Acute Mental Health Services by Patients with SchizophreniaNew England Journal of Medicine, 1994
- Effects of Medicaid Drug-Payment Limits on Admission to Hospitals and Nursing HomesNew England Journal of Medicine, 1991